BridgeBio Pharma BBIO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's EPS (diluted)?
- BridgeBio Pharma (BBIO) reported EPS (diluted) of -$0.84 in Q1 2026.
- How has BridgeBio Pharma's EPS (diluted) changed year-over-year?
- BridgeBio Pharma's EPS (diluted) increased by 4.5% year-over-year, from -$0.88 to -$0.84.
- What is the long-term trend for BridgeBio Pharma's EPS (diluted)?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EPS (diluted) has grown at a -1.0% compound annual growth rate (CAGR), from -$3.92 to -$3.77.
- What does EPS (diluted) mean?
- The profit per share assuming all potential sources of new shares were converted into actual stock.
- How do you interpret EPS (diluted)?
- A smaller gap between basic and diluted EPS indicates lower potential dilution risk for shareholders.
- How does EPS (diluted) compare across companies?
- Standard metric for assessing the impact of equity-based compensation and convertible instruments.